Comparison of Rituximab, Cyclophosphamide, and Tacrolimus As First Steroid-sparing Agents for Complicated Relapsing/steroid-dependent Nephrotic Syndrome in Children: an Evaluation of the Health-related Quality of Life

Overview

Journal Arch Med Sci

Specialty General Medicine

Date 2022 Feb 14

PMID 35154548

Authors

Li Wang

Jialiang Zhu

Mingyun Xia

Ran Hua

Fang Deng

Affiliations

Soon will be listed here.

Abstract

Introduction: Frequently-relapsing/steroid-dependent nephrotic syndrome (FRSDNS) leads to steroid toxicity impairing quality of life (QOL), thus prompting the use of steroid-sparing drugs.

Methods: 51 FRSDNS children not previously treated with steroid-sparing agents were randomized to receive rituximab, cyclophosphamide, or tacrolimus. Clinical findings and QOL were evaluated before and after treatment.

Results: The mean relapse rate in all groups declined six months after treatment, however, 1-year relapse-free survival rate, number of relapses, and cumulative prednisolone dosage were lower with rituximab than with tacrolimus and cyclophosphamide. Cyclophosphamide group had twice frequency of infections compared to the other groups. At 1 year after treatment, total scores showed greater improvement with rituximab.

Conclusions: As first-line steroid-sparing agent, rituximab is more effective and safer than cyclophosphamide and tacrolimus in FRSDNS, and improve QOL.

Citing Articles

Prolonged remission after cyclophosphamide or tacrolimus treatment in childhood nephrotic syndrome: a cohort study.

Robinson C, Aman N, Banh T, Brooke J, Chanchlani R, Dhillon V Pediatr Nephrol. 2024; .

PMID: 39576325 DOI: 10.1007/s00467-024-06605-0.

Non-corticosteroid immunosuppressive medications for steroid-sensitive nephrotic syndrome in children.

Larkins N, Hahn D, Liu I, Willis N, Craig J, Hodson E Cochrane Database Syst Rev. 2024; 11:CD002290.

PMID: 39513526 PMC: 11544715. DOI: 10.1002/14651858.CD002290.pub6.

Rituximab versus tacrolimus as corticosteroid-sparing therapy for children with steroid-dependent nephrotic syndrome: A systematic review and meta-analysis of randomized and nonrandomized controlled trials.

Ang J, Widjanarko N, Ekaputra A Tzu Chi Med J. 2024; 36(3):319-329.

PMID: 38993828 PMC: 11236076. DOI: 10.4103/tcmj.tcmj_234_23.

An update on the incidence, risk factors and mechanisms of rituximab-associated neutropenia.

Zhang X, Rao M, Xu G Arch Med Sci. 2024; 20(2):494-505.

PMID: 38757021 PMC: 11094828. DOI: 10.5114/aoms/152174.

Immunosuppressive agents for frequently relapsing/steroid-dependent nephrotic syndrome in children: a systematic review and network meta-analysis.

Zhu Y, Chen J, Zhang Y, Wang X, Wang J Front Immunol. 2024; 15:1310032.

PMID: 38464533 PMC: 10920238. DOI: 10.3389/fimmu.2024.1310032.

References

Ravani P, Lugani F, Drovandi S, Caridi G, Angeletti A, Ghiggeri G . Rituximab vs Low-Dose Mycophenolate Mofetil in Recurrence of Steroid-Dependent Nephrotic Syndrome in Children and Young Adults: A Randomized Clinical Trial. JAMA Pediatr. 2021; 175(6):631-632. PMC: 7900932. DOI: 10.1001/jamapediatrics.2020.6150. View

Takahashi T, Okamoto T, Yokota I, Sato Y, Hayashi A, Ueda Y . The effect of rituximab on the quality of life of children with refractory nephrotic syndrome. Pediatr Int. 2021; 64(1):e14725. DOI: 10.1111/ped.14725. View

Ravani P, Lugani F, Pisani I, Bodria M, Piaggio G, Bartolomeo D . Rituximab for very low dose steroid-dependent nephrotic syndrome in children: a randomized controlled study. Pediatr Nephrol. 2020; 35(8):1437-1444. DOI: 10.1007/s00467-020-04540-4. View

Chan E, Webb H, Yu E, Ghiggeri G, Kemper M, Ma A . Both the rituximab dose and maintenance immunosuppression in steroid-dependent/frequently-relapsing nephrotic syndrome have important effects on outcomes. Kidney Int. 2019; 97(2):393-401. DOI: 10.1016/j.kint.2019.09.033. View

Sinha A, Bhatia D, Gulati A, Rawat M, Dinda A, Hari P . Efficacy and safety of rituximab in children with difficult-to-treat nephrotic syndrome. Nephrol Dial Transplant. 2014; 30(1):96-106. DOI: 10.1093/ndt/gfu267. View

Subun C, Suwannahitatorn P, Webb H, Tullus K . Rituximab in childhood steroid-sensitive nephrotic syndrome: are multiple subsequent courses safe and effective?. Arch Dis Child. 2020; 106(8):815-818. DOI: 10.1136/archdischild-2020-319609. View

Kari J, Alhasan K, Albanna A, Safdar O, Shalaby M, Bockenhauer D . Rituximab versus cyclophosphamide as first steroid-sparing agent in childhood frequently relapsing and steroid-dependent nephrotic syndrome. Pediatr Nephrol. 2020; 35(8):1445-1453. DOI: 10.1007/s00467-020-04570-y. View

Ahmed H . Tacrolimus can induce remission in cyclosporine and mycophenolate mofetil resistant pediatric onset nephrotic syndrome. Iran J Kidney Dis. 2019; 13(5):322-327. View

Fujimoto K, Kagaya Y, Kumano S, Fujii A, Tsuruyama Y, Matsuura T . Retrospective single-arm cohort study of steroid-dependent minimal change nephrotic syndrome treated with very low-dose rituximab. Clin Nephrol. 2020; 95(1):29-36. DOI: 10.5414/CN110245. View

10.

Basu B, Sander A, Roy B, Preussler S, Barua S, Mahapatra T . Efficacy of Rituximab vs Tacrolimus in Pediatric Corticosteroid-Dependent Nephrotic Syndrome: A Randomized Clinical Trial. JAMA Pediatr. 2018; 172(8):757-764. PMC: 6142920. DOI: 10.1001/jamapediatrics.2018.1323. View

11.

Tan L, Li S, Yang H, Zou Q, Wan J, Li Q . Efficacy and acceptability of immunosuppressive agents for pediatric frequently-relapsing and steroid-dependent nephrotic syndrome: A network meta-analysis of randomized controlled trials. Medicine (Baltimore). 2019; 98(22):e15927. PMC: 6709258. DOI: 10.1097/MD.0000000000015927. View

12.

Roussel A, Delbet J, Micheland L, Deschenes G, Decramer S, Ulinski T . Quality of life in children with severe forms of idiopathic nephrotic syndrome in stable remission-A cross-sectional study. Acta Paediatr. 2019; 108(12):2267-2273. DOI: 10.1111/apa.14912. View

13.

Wang L, Hua R, Zhu Y, Lu Y, Gao H, Xia X . Single Dose of Rituximab in Children with Steroid-Dependent / Frequently Relapsing Nephrotic Syndrome, Clinical Efficacy and Evaluation of Health-Related Quality of Life. Iran J Kidney Dis. 2021; 1(2):109-115. View

14.

Khullar S, Banh T, Vasilevska-Ristovska J, Chanchlani R, Brooke J, Licht C . Impact of steroids and steroid-sparing agents on quality of life in children with nephrotic syndrome. Pediatr Nephrol. 2020; 36(1):93-102. DOI: 10.1007/s00467-020-04684-3. View

15.

Larkins N, Liu I, Willis N, Craig J, Hodson E . Non-corticosteroid immunosuppressive medications for steroid-sensitive nephrotic syndrome in children. Cochrane Database Syst Rev. 2020; 4:CD002290. PMC: 7160055. DOI: 10.1002/14651858.CD002290.pub5. View